Marthe Fourcade

Jun 10, 2024 | bnnbloomberg.ca | Marthe Fourcade

(Bloomberg) -- Ipsen SA and partner Genfit SA won US regulators’ clearance for the first new treatment option in eight years for patients with a rare liver disease. The US Food and Drug Administration approved the medicine, elafibranor, for adults with primary biliary cholangitis, an autoimmune disease in which the bile ducts become inflamed and slowly destroyed. The drug will be called Iqirvo, Ipsen said in a statement Monday.

Jun 10, 2024 | bloomberg.com | Marthe Fourcade

Ipsen SA and partner Genfit SA won US regulators’ clearance for the first new treatment option in eight years for patients with a rare liver disease. The US Food and Drug Administration approved the medicine, elafibranor, for adults with primary biliary cholangitis, an autoimmune disease in which the bile ducts become inflamed and slowly destroyed. The drug will be called Iqirvo, Ipsen said in a statement Monday.

May 27, 2024 | bnnbloomberg.ca | Marthe Fourcade

(Bloomberg) -- AstraZeneca Plc and partner Daiichi Sankyo Co.’s experimental drug Dato-DXd helped extend the lives of some lung cancer patients in a late-stage study. The drug already showed it could stave off cancer’s worsening last year. Now, researchers have looked at the data to determine whether it actually helped prolong patients’ lives — a key gauge called overall survival.

May 27, 2024 | bloomberg.com | Marthe Fourcade

AstraZeneca Plc and partner Daiichi Sankyo Co.’s experimental drug Dato-DXd helped extend the lives of some lung cancer patients in a late-stage study. The drug already showed it could stave off cancer’s worsening last year. Now, researchers have looked at the data to determine whether it actually helped prolong patients’ lives — a key gauge called overall survival.

May 21, 2024 | bnnbloomberg.ca | Marthe Fourcade

(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing. The decision is based on research showing the medicine, called inavolisib, could offer a more effective first treatment option for women with a particular breast cancer mutation.